Trav4d-3 Inhibitors
Trav4d-3 inhibitors are a specialized class of chemical compounds that interact with the Trav4d-3 protein or receptor, blocking its biological function by specifically binding to its active or regulatory sites. These inhibitors work by preventing the natural substrates or ligands from engaging with the Trav4d-3 protein, thereby reducing or altering its normal activity within biochemical pathways. Typically, this inhibition occurs through non-covalent interactions, including hydrogen bonding, van der Waals forces, ionic interactions, and hydrophobic contacts. These interactions ensure that the inhibitor can effectively attach to the Trav4d-3 protein, stabilizing the interaction and preventing the protein from carrying out its intended function. Depending on the mechanism, some Trav4d-3 inhibitors may bind to the protein's active site directly, while others may exert their influence by attaching to allosteric sites, causing structural changes that reduce the protein's activity.
The chemical structure of Trav4d-3 inhibitors can vary significantly depending on the desired specificity and binding affinity. These compounds often incorporate key structural features such as aromatic rings, heterocyclic systems, and various functional groups like hydroxyl, amine, or carboxyl groups, which facilitate precise binding with the Trav4d-3 protein. The design of these inhibitors often emphasizes optimizing molecular properties, such as size, shape, and polarity, to ensure they fit well within the protein's binding site and form stable interactions. Furthermore, the balance of hydrophobic and hydrophilic regions within the inhibitor molecule is crucial for determining solubility and interaction efficiency. Hydrophobic regions are often essential for binding to non-polar pockets of the protein, while hydrophilic groups can enhance solubility and provide additional binding strength through hydrogen bonding or electrostatic interactions. By tailoring these physicochemical properties, Trav4d-3 inhibitors can be finely tuned for optimal binding and activity, allowing them to effectively modulate the function of the Trav4d-3 protein under various conditions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib selectively inhibits cyclin-dependent kinases CDK4 and CDK6. Since Trav4d-3 is a protein that may be regulated by the cell cycle, inhibiting these kinases could halt the cell cycle, thereby inhibiting the function of proteins that are dependent on cell cycle progression, including Trav4d-3. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR (mammalian target of rapamycin), which is a key regulator of protein synthesis and cell growth. Inhibition of mTOR could lead to reduced activity of proteins that are downstream of the mTOR pathway, potentially including Trav4d-3 if it is involved in such growth regulatory pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of PI3K (phosphoinositide 3-kinases). PI3K/Akt signaling is crucial for many cellular processes, including protein synthesis. If Trav4d-3 function is PI3K/Akt pathway-dependent, its inhibition could lead to a decrease in Trav4d-3 activity. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib inhibits MEK1/2, which are upstream regulators of the ERK pathway, involved in cell proliferation and survival. Inhibition of this pathway could decrease the function of proteins such as Trav4d-3 if it is regulated by the ERK signaling pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, like Trametinib, and would similarly inhibit the ERK pathway, potentially leading to a decrease in Trav4d-3 activity if it is regulated by this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinase), which is involved in stress-activated protein kinase signaling. If Trav4d-3 is regulated by JNK, then its inhibition could decrease Trav4d-3 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. The p38 MAP kinase pathway is involved in inflammatory responses and apoptosis. Inhibition of this pathway could lead to decreased Trav4d-3 activity if it plays a role in the pathway. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib inhibits Bcr-Abl tyrosine kinase as well as other tyrosine kinases like c-Kit and PDGFR. If Trav4d-3 activity is influenced by these kinases, imatinib could lead to functional inhibition of Trav4d-3 through these pathways. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib selectively inhibits epidermal growth factor receptor (EGFR) tyrosine kinase. If Trav4d-3 function involves EGFR signaling, its inhibition could lead to decreased activity of Trav4d-3. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an inhibitor of EGFR tyrosine kinase, similar to Gefitinib, and would similarly lead to decreased Trav4d-3 activity if Trav4d-3 is part of the EGFR signaling pathway. | ||||||